Chest
-
Multicenter Study Clinical Trial Controlled Clinical Trial
Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients.
The positive inotropic and vasodilator actions of phosphodiesterase (PDE) inhibitor drugs may offer therapeutic alternatives to beta-agonists in critically ill patients. We hypothesized that milrinone administration would increase cardiac index (CI) and oxygen delivery (Do2) in ICU patients, and that a pharmacokinetic model previously developed in cardiac surgery patients may be used to predict milrinone plasma concentrations in a medical-surgical ICU population. ⋯ Our study confirms that a milrinone loading dose of 50 micrograms/kg/min followed by an infusion of 0.5 microgram/kg/min achieves adequate plasma concentrations of 100 ng/mL or greater, which significantly increases both CI and Do2. In addition, a previously established pharmacokinetic model of milrinone disposition is confirmed in this mixed ICU population.
-
Review Multicenter Study
Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase.
We report the results of image-guided catheter drainage with adjunctive enzymatic pleural debridement in the treatment of empyemas and other complicated pleural fluid collections. ⋯ Image-guided drainage with adjunctive pleural urokinase therapy is a safe and effective method of closed thoracostomy drainage of complicated pleural fluid collections and can obviate surgery in most cases.
-
Multicenter Study
Predicting death in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Extracorporeal Life Support Organization.
To estimate mortality risk in pediatric patients with acute hypoxemic respiratory failure (AHRF). ⋯ The PeRF Score accurately estimated mortality risk in this retrospectively sampled group of high-risk pediatric patients with AHRF. This score may be useful in studies of newer therapies for pediatric AHRF, though prospective validation is necessary before it could be used to make clinical decisions.
-
Multicenter Study Clinical Trial Controlled Clinical Trial
Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.
Mycobacterium avium complex infections, common in patients with AIDS as either pulmonary or disseminated disease, are infrequent in patients without AIDS. Participants were 45 HIV-negative patients with lung disease and positive sputum cultures for M avium; 10 had documented immunocompromise, and 24 had preexisting lung disease. Clarithromycin dosage was 500 to 2,000 mg daily (mean +/- SD = 1,633 +/- 432 mg). ⋯ During the follow-up, one patient suffered a relapse with peripheral lymph nodes. A daily dose of 30 mg/kg of clarithromycin in the treatment of M avium infections appears to be effective and safe. Concomitant drug therapy should be assessed for its ability to prevent relapse.
-
Multicenter Study
Hospital survival rates of patients with acute respiratory failure in modern respiratory intensive care units. An international, multicenter, prospective survey.
An international, multicenter, prospective survey has been conducted to determine the hospital survival rates of patients with potentially reversible acute respiratory failure (ARF) who are managed in sophisticated intensive care units by leading critical care specialists, using current (1991 to 1992) support and treatment techniques and protocols. Twenty-five clinical centers participated in the survey, 11 in the United States and 14 in Europe. A total of 1,426 patients with ARF were studied, all of whom had been receiving closed system positive pressure mechanical ventilation at an FIo2 of at least 0.50 for at least 24 h at the time of entry into the survey. ⋯ Peak inspiratory pressure (PIP) > 50 cm H2O at entry into the survey was associated with survival rate of less than 20%, while PIP < 30 cm H2O was associated with survival rate of 60%. Shorter periods of mechanical ventilation (< 48 h) of group A patients before entering the survey were associated with higher survival rates (38%) than patients requiring mechanical ventilation for more than 2 weeks (30%). Patients with ARF with multiorgan failure had lower survival rates (10%) than those with pulmonary dysfunction alone (45%).(ABSTRACT TRUNCATED AT 400 WORDS)